Oct 10, 2019 / 03:30PM GMT
Operator
Good day, and welcome to the Alnylam Pharmaceuticals RNAi Roundtable. Today's conference is being recorded.
At this time, I would like to turn the conference over to Mr. Josh Brodsky, Director of Investor Relations and Corporate Communications. Please go ahead, sir.
Joshua Brodsky - Alnylam Pharmaceuticals, Inc. - Director of IR & Corporate Communications
Good morning, everyone. Thank you for joining us for today's RNAi Roundtable, where we'll be discussing lumasiran in development for the treatment of primary hyperoxaluria type 1. I'm Josh Brodsky, Director of Investor Relations and Corporate Communications at Alnylam. With me today are Pritesh Gandhi, Vice President and General Manager of the Lumasiran Program; Dr. Kenji Fujita, Vice President of Clinical Development; Dr. Elaine Worcester of the University of Chicago; and Andrew, a patient diagnosed with PH1, who is joining us, along with his wife and caregiver, Nicole.
Today's RNAi Roundtable is part of a series of roundtables that we are hosting this year. Today's event is expected to
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1 Transcript
Oct 10, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers